<DOC>
	<DOCNO>NCT02536625</DOCNO>
	<brief_summary>NK ( Natural Killer ) cell important fight tumor , especially control cancer metastasis . The purpose prospective study evaluate impact lymphocytes NK function development everolimus treatment woman treat metastatic breast cancer . In particular , study lymphocyte NK function development everolimus treatment could permit validate early biomarker impact everolimus NK cell .</brief_summary>
	<brief_title>Study Impact Everolimus Treatment Lymphocytes NK ( Natural Killer ) Development Functions Patients With Metastatic Breast Cancer ( HR+ / HER2/Neu Negative )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Women &gt; 18 year old Metastatic breast cancer HR+ ( Hormone Receptor positive ) , HER2/neu negative ( Human Epidermal Growth Factor Receptor2 ) ECOG PS ( Eastern Cooperative Oncology Group Performance Status ) ≤2 Eligible hormonotherapy treatment combine mTOR ( mammalian Target Of Rapamycin ) inhibitor ( i.e . SPC ( Summary Product Characteristics ) modality ) Measurable disease accord RECIST 1.1 ( Response Evaluation Criteria In Solid Tumors ) Not receive nonauthorized concomitant treatment Patient understand , sign , date write voluntary informed consent form screen visit prior protocolspecific procedure perform . Patients must cover medical insurance BMI &gt; 30 All dysimmune disease , history transplantation immunosuppressive therapy corticotherapy All chronic inflammatory disease Last chemotherapy &lt; 6 month Corticotherapy &lt; 1 year 1 month Restrictive diet ≤3 month inclusion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>everolimus</keyword>
	<keyword>NK</keyword>
	<keyword>metastatic</keyword>
</DOC>